OKYO Pharma Announces Successful Type C Meeting with the FDA

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004

CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 ...

FDA cancels meeting to choose flu strains for next year's vaccine

The Food and Drug Administration Wednesday abruptly and unexpectedly cancelled a planned March 13 vaccine advisory committee meeting that was to have chosen the flu strains in next year's U.S. flu ...

Epirium Bio Announces Positive Type C (End-of-Phase 1) Meeting with FDA Supporting Advancement of MF-300 to a Phase 2b Clinical Trial in Sarcopenia

Epirium Bio Inc. (Epirium), a clinical-stage biopharmaceutical company advancing medicines for neuromuscular, immunological and fibrotic diseases, today announced outcomes from its Type C meeting with ...
Ophthalmology Times

Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula

CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...
ALS News Today

Clene, FDA to discuss survival data and approval path for CNM-Au8

Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy for ALS.

Zyn is seeking FDA approval to say it’s less harmful than cigarettes

Videos from “Zynfluencers” have racked up tens of millions of views on social media platforms in recent years.
Blockonomi

ImmunityBio (IBRX) Stock Jumps 20% as FDA Clears Path for Bladder Cancer Treatment

ImmunityBio stock rose 19.8% after FDA meeting on ANKTIVA bladder cancer treatment. Company to submit additional data within ...
CSNews

FDA to Meet With Stakeholders on ENDS Applications

A Feb. 10 meeting is open to to 30 individuals representing manufacturers who have previously submitted an ENDS premarket ...

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...

ImmunityBio Shares Hit 52-Week high After FDA Meeting on Anktiva

ImmunityBio shares were 36% higher, at $7.52, after the company said it recently held a Type B End-of-Phase meeting with the Food and Drug Administration regarding its supplemental Biologics License ...